Halozyme Therapeutics, Inc. (HALO) on Decifer

Decifer ranks HALO number 14 of 276 tracked names on durable business quality.

Why it ranks here

• It earns strong returns on the money it puts to work, around 24% and it turns most of its profit into real cash.
• Revenue is growing about 38% a year, profits are expected to grow 25%, and growth is speeding up, not slowing down.
• It keeps a high share of every sale as profit, and that has stayed steady over the years, a sign of real pricing power.
• and has the balance sheet to fund its growth.
• It is not watering down its owners with new shares and it returns cash to shareholders.
• As the single credible supplier of formulation technology for specialty biologics on a green watchboard with returns around 24% and revenue growing about 38% a year, this partly recognized chokepoint role stands out with momentum of 20 out of 35.

The current read

The evidence on HALO lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

• Healthcare, Biotech & Devices: Halozyme Therapeutics, Inc. operates in biotechnology. That places it inside the Healthcare, Biotech & Devices story.

Read the full HALO research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.